Drug Profile
Interferon alpha-2b/interferon gamma - Heber Biotech
Alternative Names: CIGB-128; CIGB-128-A; HeberFERON; HeberPAG; Interferon-alpha-2b/interferon-gamma; Interferon-gamma/interferon-alpha-2bLatest Information Update: 27 Sep 2022
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology
- Class Antineoplastics; Antivirals; Interferons; Lymphokines; Recombinant proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Basal cell cancer; COVID 2019 infections
- No development reported Brain cancer; Mycosis fungoides
Most Recent Events
- 27 Sep 2022 Phase-II development in COVID-2019 infections is ongoing in Cuba (SC) (RPCEC00000307)
- 10 Apr 2020 Phase-II clinical trials in COVID-2019 infections in Cuba (SC) (RPCEC00000307)
- 28 Feb 2018 No recent reports of development identified for phase-I development in Mycosis-fungoides in Cuba (IM)